Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 2/20 | 0.73 |
| ▸ | DRD2 | P14416 | 6/20 | 0.65 |
| ▸ | HTR2A | P28223 | 5/20 | 0.65 |
| ▸ | HTR1A | P08908 | 5/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | HTR7 | P34969 | 2/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6359140 | 0.87 | DRD4 (0.60) | DRD4DRD2HTR2AHTR1AKDM4E | |
| SCHEMBL6354025 | 0.84 | DRD4 (1.00) | DRD4DRD2HTR2AHTR1AHTR7 | |
| SCHEMBL6359534 | 0.84 | DRD4 (1.00) | DRD4DRD2HTR2AHTR1AHTR7 | |
| SCHEMBL6354027 | 0.84 | DRD4 (1.00) | DRD4DRD2HTR2AHTR1AHTR7 | |
| SCHEMBL6357616 | 0.83 | HTR1A (0.70) | DRD4DRD2HTR1AKDM4E | |
| SCHEMBL6360620 | 0.82 | HTR1A (0.69) | DRD4HTR1A | |
| SCHEMBL4006923 | 0.81 | DRD4 (0.71) | DRD4DRD2HTR2AKDM4ERECQL | |
| SCHEMBL6352207 | 0.79 | DRD4 (1.00) | DRD4DRD2HTR2A | |
| SCHEMBL6352204 | 0.79 | DRD4 (1.00) | DRD4DRD2HTR2A | |
| SCHEMBL6360134 | 0.79 | HTR1A (1.00) | DRD4DRD2HTR2AHTR1AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050176727-A1 | Oximes and hydrazones that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176727-A1 | Oximes and hydrazones that are useful in treating sexual dysfunction | CYP19A1, SHBG, CYP17A1 | DRD4 1272/4885DRD2 1704/4885HTR2A 1588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.